AOD-9604 Missed-Dose Protocol: What to Do If You Skip an Injection

How AOD-9604 Works, and What the Evidence Actually Shows

AOD-9604 is a synthetic peptide built from the last 15 amino acids of the human growth hormone molecule (residues 177-191), with an added tyrosine at the N-terminus. It was designed to retain the fat-metabolizing activity of growth hormone while avoiding GH-receptor activation and the IGF-1 effects that make full-length GH therapy inappropriate for most people seeking fat loss.

The foundational data here come from animal research. Heffernan et al. showed that this C-terminal fragment stimulated lipolysis and reduced fat gain in obese mice without activating the GH receptor or raising IGF-1 1. A related study by Ng et al. examined metabolic effects of the same synthetic lipolytic domain 2. Both are preclinical, animal-model studies. Human trial evidence for AOD-9604's fat-loss effect is limited, and the original sponsor's clinical development program did not continue past exploratory human obesity trials. Before this page makes any claim about expected results in humans, an editor should verify the current state of published human trial data; until that is confirmed, treat the mechanism described here as biologically plausible and supported in animals, not as proof of a clinical effect in people.

Because AOD-9604 has a short plasma half-life, its lipolytic action is thought to occur in discrete windows tied to each injection rather than building up in the body. This matters for missed-dose thinking: skipping one dose does not create a hormone "deficit" the way skipping a longer-acting hormone might, but a pattern of repeated missed doses would reduce the total number of these windows across a course of treatment.

The General Same-Day Rule for a Missed Injection

The commonly used rule of thumb is to take the missed dose the same day if at least 12 hours remain before the next scheduled dose, and to skip it and resume the normal schedule the next day if less time remains.

This 12-hour figure is a general pharmacological safety buffer, not a result from an AOD-9604-specific missed-dose trial. No published study has tested missed-dose timing for this peptide in humans, so this guidance is extrapolated from general practice for short-acting injectables. General drug-safety guidance advises against doubling any injectable medication dose unless the product's own labeling explicitly supports it, and no AOD-9604 compounding monograph authorizes double-dosing. Because AOD-9604 has no FDA label at all, there is no labeled instruction to defer to here, only general practice and your prescriber's specific protocol.

If your prescriber has given you a specific missed-dose instruction that differs from this general rule, follow theirs. Compounding pharmacies and prescribers can reasonably set protocols that differ from general injectable-peptide practice based on your formulation, concentration, and health history.

Why Doubling a Dose Is Not Recommended

Doubling an AOD-9604 dose to "catch up" is not supported by any dosing guidance for this peptide, and it introduces risk without a documented benefit.

Lipolytic signaling through adrenergic receptor pathways is generally understood to follow a saturation pattern rather than a straight-line dose response, meaning that once available receptors are engaged, additional peptide is not expected to recruit further effect. The Ng et al. metabolic study of the AOD-9604 fragment examined dosing effects in an animal model 2; an editor should confirm the exact quantitative findings (including any injection-site effects reported) before this page cites specific numbers from that study, since the abstract-level description available here does not support a precise figure.

Practical reasons not to double up:

• No compounding monograph or prescriber protocol for AOD-9604 authorizes a doubled dose
• A larger injected volume at one site raises the chance of local discomfort, swelling, or bruising
• Patients who "make up" a missed dose sometimes feel licensed to skip the following day, which can turn an isolated miss into an irregular pattern

If the 12-hour window has closed, the practical option is to accept the gap and resume on schedule. One missed dose in a 30-day course is a small fraction of total planned doses; whether that fraction is clinically meaningful for you specifically is a question for your prescriber, not a general rule this article can answer.

Handling Multiple Consecutive Missed Doses

If you miss two or more consecutive days, resume your standard dose at the next scheduled time rather than adding extra doses to compensate. Contact your prescribing clinician if you miss three or more consecutive days so they can reassess your protocol and check whether side effects, cost, storage problems, or scheduling conflicts are driving the pattern.

A run of missed doses is sometimes caused by a vial that has lost potency rather than a memory lapse. Peptide and protein-based drug products are generally understood to be sensitive to temperature excursion and degrade faster when stored improperly 3; this is a general protein-stability principle rather than an AOD-9604-specific finding. If your solution has turned cloudy, changed color, or sat at room temperature for more than a few hours, do not inject it. Discard it and reconstitute a fresh vial, and ask your pharmacy whether a replacement is needed.

Clinician Conversation and Monitoring Framework

There is no FDA label for AOD-9604, so nothing in this article, including the 12-hour rule above, is "labeled dosing guidance." It is general practice reasoning about short-acting injectable peptides. Your individualized plan, including how your specific prescriber and compounding pharmacy want missed doses handled, takes priority over anything general on this page. Use the checkpoints below to structure that conversation rather than to self-manage a growing pattern of missed or altered doses.

Routine checkpoints to bring to your prescriber

Stop and seek prompt medical care if you notice

• Signs of an allergic reaction: hives, swelling of the face, lips, or throat, or difficulty breathing after an injection
• Symptoms suggesting significant low blood sugar (shakiness, confusion, cold sweat) after a dose, especially if you also take metformin, an SGLT2 inhibitor, insulin, or another glucose-lowering medication
• Redness, warmth, worsening pain, or drainage at an injection site that suggests infection rather than ordinary post-injection irritation
• Any symptom you cannot explain that started after a missed dose, a doubled dose, or an injection from a vial you were unsure about

Where general guidance ends and individualized care begins

General guidance, including everything in this article, can tell you the common practice pattern for short-acting injectable peptides. It cannot tell you whether that pattern fits your kidney or liver function, your other medications, your glucose control, or the specific formulation and concentration your pharmacy compounded. Ask your prescriber to state explicitly, in writing if possible, what they want you to do if you miss one dose, miss several in a row, or are unsure about a vial, so you are not relying on general reasoning during a real decision.

Timing Your Dose Relative to Food

Many compounded AOD-9604 protocols direct patients to inject after an overnight or several-hour fast and to wait roughly 30 minutes before eating. The underlying reasoning is that insulin and postprandial nutrient competition may reduce peptide absorption or interfere with the lipolytic signal, a general pharmacokinetic concept for subcutaneously injected peptides. A specific bioavailability difference for fasted versus fed AOD-9604 injections in humans has not been established in the sources available for this article, so this page will not state a percentage figure. If a source publishes that figure for this compound specifically, it should be added with its own citation rather than borrowed from an unrelated peptide's pharmacokinetic study.

If you eat before your scheduled injection and are unsure whether to proceed, ask your prescriber how they want you to handle it rather than defaulting to either skipping the dose or injecting regardless.

Storage and Reconstitution Factors That Affect Dosing Consistency

A dose that looks "missed" is sometimes really a dose administered from a vial that had already lost potency. AOD-9604 is supplied as a lyophilized powder and reconstituted with bacteriostatic water before use. The CDC's guidance on multi-dose vial handling emphasizes labeling reconstituted vials with the date of reconstitution and discarding them once the pharmacy's beyond-use date passes.

General storage practices for a reconstituted peptide like this:

• Do not freeze the reconstituted solution
• Keep the vial upright and refrigerated rather than in a door shelf subject to temperature swings
• Use an insulated cooler with ice packs when traveling, without letting the vial contact ice directly
• Inspect the solution before each injection; it should be clear and colorless

If you notice particulate matter, cloudiness, or discoloration, do not inject it. Contact your pharmacy about a replacement.

Because AOD-9604 reaches patients through the 503A compounding pathway rather than an FDA-approved product, its regulatory status as a compounded substance is itself something to confirm rather than assume. The FDA maintains guidance on which bulk drug substances may lawfully be used in 503A compounding, and that determination can change. An editor or clinician should check the current status before this page states anything definitive about AOD-9604's compounding eligibility.

How AOD-9604 Differs from Growth Hormone Therapy in Missed-Dose Handling

Patients moving from growth hormone therapy to AOD-9604 sometimes apply GH missed-dose habits, which do not transfer cleanly.

Full-length growth hormone (somatropin) has a longer plasma half-life and drives IGF-1 production that persists for many hours. The Endocrine Society's clinical practice guideline on hormonal replacement in hypopituitarism describes a structured, monitored approach to GH replacement that includes IGF-1 tracking. That framework exists because GH replacement is FDA-approved, has an established label, and is monitored with a specific lab marker.

AOD-9604 does not raise IGF-1 and is not thought to act through the GH receptor at all, based on the animal data from Heffernan et al. 1. That means there is no equivalent lab marker to monitor after a missed dose, and no FDA-approved monitoring framework to fall back on. A missed GH dose can produce noticeable symptoms in someone dependent on replacement therapy; a missed AOD-9604 dose is not expected to produce an acute symptom, though this expectation rests on the mechanism data rather than a dedicated missed-dose study in humans.

Professional societies such as the Endocrine Society and the American Association of Clinical Endocrinology publish general practice guidelines on hormone and peptide therapy management, but neither currently publishes an AOD-9604-specific protocol. General statements about "peptide therapeutics" attributed to these organizations should not be presented as direct quotations unless a specific, dated, publicly available document is cited; this draft removes an earlier quotation that could not be traced to a specific source.

When to Contact Your Prescriber About Missed Doses

Contact your prescriber if any of the following apply: you have missed three or more doses in a 14-day period, you are missing doses because of side effects such as nausea, injection-site reactions, or headaches, you are unsure whether your reconstituted vial is still viable, or you are combining AOD-9604 with other peptides and are unsure how a missed dose affects the combined protocol.

Your prescriber can also discuss whether an alternate-day schedule at a different per-injection amount fits your situation better than daily dosing. This kind of change has less supporting data than a daily protocol and should be treated as an individualized clinical decision rather than something to try on your own.